Frontiers in Oncology, section “Genitourinary Oncology” |
| Prostate Cancer and New Insights in Angiogenesis |
| Sanja Stifter and Gordana Đorđević |
| Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer? |
| Takeo Kosaka, Akira Miyajima, and Mototsugu Oya |
| Circulating Type-1 Anti-Tumor CD4+ T Cells are Preferentially Pro-Apoptotic in Cancer Patients |
| Amy K. Wesa, Maja Mandic, Jennifer L. Taylor, Stergios Moschos, John M. Kirkwood, William W. Kwok, James Harold Finke, and Walter J. Storkus |
Frontiers in Oncology, section “Head and Neck Cancer” |
| The Potential Diagnostic Role of the Number of Ultrasonographic Characteristics for Patients with Thyroid Nodules Evaluated as Bethesda I–V |
| Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Satoshi Iizuka, Kimiko Hoshino, Kanako Hatanaka, Koji Oba, and Satoshi Fukuda |
Frontiers in Oncology, section “Molecular and Cellular Oncology” |
| Inflammatory Breast Cancer: High Incidence of Detection of Mixed Human Cytomegalovirus Genotypes Associated with Disease Pathogenesis |
| Hossam Taha Mohamed, Mohamed El-Shinawi, M. Akram Nouh, Elsayed Tarek Elsayed, Abdel-Rahman Bashtar, Robert J. Schneider, and Mona Mostafa Mohamed |
| Laser Microdissection of the Alveolar Duct Enables Single-Cell Genomic Analysis |
| Robert Bennett, Alexandra Ysasi, Janeil Belle, Willi Wagner, Moritz A. Konerding, Paul Clark Blainey, Saumyadipta Pyne, and Steven J. Mentzer |
| Metabostemness: A New Cancer Hallmark |
| JAVIER A MENENDEZ and TOMÁS ALARCÓN |
| Cytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme |
| Andrea Schuessler, David Walker, and Rajiv Khanna |
| Extracellular Vesicles as Shuttles of Tumor Biomarkers and Anti-Tumor Drugs |
| Davide Zocco, Pietro Ferruzzi, Francesco Cappello, Winston Patrick Kuo, and Stefano Fais |
| Molecular Characterization of the Dominant-Negative Role of Cancer-Associated PTEN: Sometimes, Null is Better |
| Paolo Pinton and Saverio Marchi |
| p53 Family and Cellular Stress Responses in Cancer |
| Johanna Pflaum, Sophie Schlosser, and Martina Müller |
Frontiers in Oncology, section “Radiation Oncology” |
| Image-Guided Radiotherapy for Cardiac Sparing in Patients with Left-Sided Breast Cancer |
| Claire LEMANSKI, Juliettte Thariat, Fred Ampil, Satya Bose, Jacqueline Vock, Rick Davis, Alexander Chi, Suresh Dutta, William Woods, Anand Desai, Juan Godinez, ULF LENNART Karlsson, Nam Phong Nguyen, and Vincent Vinh-Hung |
|
|
Frontiers in Oncology, section “Radiation Oncology” (Continued) |
| Intersection of Cardiology and Oncology Clinical Practices |
| Farouk Mookadam, Ashwini Sharma, Howard Lee, and Donald Northfelt |
| The Utility of Positron Emission Tomography in the Treatment Planning of Image-Guided Radiotherapy for Non-Small Cell Lung Cancer |
| Alexander Chi and Nam Phong Nguyen |
| Cardiac Avoidance in Breast Radiotherapy: Many Choices for a Worthwhile Objective |
| Atif J Khan, Sharad Goyal, and Frank A Vicini |
| Stereotactic Body Radiotherapy as Primary Therapy for Head and Neck Cancer in the Elderly or Patients with Poor Performance |
| Arya Amini, Jessica D McDermott, Gregory Gan, Shilpa Bhatia, Whitney Sumner, Christine Fisher, Antonio Jimeno, Daniel W Bowles, David Raben, and Sana Karam |
| Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients |
| Sibo Tian, Kim M Hirshfield, Salma K Jabbour, Deborah Toppmeyer, Bruce George Haffty, Atif J Khan, and Sharad Goyal |
| Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Small Academic Hospital Experience |
| Oren B Factor, Charles C Vu, Jeffrey G Schneider, Matthew R Witten, Scott L Schubach, Alicia E Gittleman, Donna T Catell, and Jonathan A Haas |
| IMRT with Stereotactic Body Radiotherapy Boost for High Risk Malignant Salivary Gland Malignancies: A Case Series |
| Sana D Karam, Abdul Rashid, James W Snider, Margaux Wooster, Shilpa Bhatia, Ann K Jay, Kenneth Newkirk, Bruce Davidson, and K. William Harter |
| Improved Irritative Voiding Symptoms 3 Years after Stereotactic Body Radiation Therapy for Prostate Cancer |
| Zakie Rana, Robyn A Cyr, Leonard N Chen, Brian S Kim, Rudy A Moures, Thomas M Yung, Siyuan Lei, Brian Timothy Collins, Simeng Suy, Anatoly Dritschilo, John H Lynch, and Sean P Collins |
| Measurement of Mean Cardiac Dose for Various Breast Irradiation Techniques and Corresponding Risk of Major Cardiovascular Event |
| Tomas Rodrigo Merino Lara, Emmanuelle Fleury, Shahram Mashouf, Joelle Helou, Claire McCann, Mark Ruschin, Anthony Kim, Nadiya Makhani, and Jean-Philippe Pignol |
Frontiers in Oncology, section “Thoracic Oncology” |
| Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials |
| Barbara Melosky |
| The Management of Brain Metastases in Non-Small Cell Lung Cancer |
| Scott Owen and Luis Souhami |
| Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs |
| Vera Hirsh and Barbara Melosky |
| Optimizing Tissue Sampling for the Diagnosis, Subtyping, and Molecular Analysis of Lung Cancer |
| Linda Marie Ofiara, Asma Navasakulpong, Stephane Beaudoin, and Anne Valerie Gonzalez |
| Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine |
| Donna Marie Graham and Natasha Leighl |
| Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer |
| Barbara Melosky |
| Hidden Treasures in “Ancient” Microarrays: Gene-Expression Portrays Biology and Potential Resistance Pathways of Major Lung Cancer Subtypes and Normal Tissue |
| Konstantinos Kerkentzes, Vincenzo Lagani, Ioannis Tsamardinos, Mogens Vyberg, and Oluf Dimitri Røe |
| Role of Radiotherapy in Metastatic Non-Small Cell Lung Cancer |
| Sergio L. Faria |
| A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells as a Blood-Based Tumor Marker in Patients with Extensive Small-Cell Lung Cancer |
| Chao H Huang, Jo Wick, Gurusingham (Sitta) Sittampalam, Victor Sanjit Nirmalanandhan, Apar Ganti, Stephen K Williamson, Prakash C Neupane, Andrew Godwin, Sarah Schmitt, Nora J Smart, Sarah Spencer, and Peter J Van Veldhuizen |
| Immunotherapy for Lung Cancer: Has it Finally Arrived? |
| Ahmed A. Mostafa and Don Gordon Morris |
Frontiers in Oncology, section “Tumor Immunity” |
| Multimodal Cancer Therapy Involving Oncolytic Newcastle Disease Virus, Autologous Immune Cells, and Bi-Specific Antibodies |
| Volker Schirrmacher and Philippe Fournier |
| Involvement of Platelet–Tumor Cell Interaction in Immune Evasion. Potential Role of Podocalyxin-Like Protein 1 |
| Laura Amo, Estibaliz Tamayo-Orbegozo, Natalia Maruri, Cristina Eguizabal, Olatz Zenarruzabeitia, Marta Riñón, Arantza Arrieta, Silvia Santos, Jorge Monge, Miguel Angel Vesga, Francisco Borrego, and Susana Larrucea |
| Cancer Immunotherapy and Next-Generation Clinical Immune Assessment |
| Chao Ma |
| Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells |
| Matjaz Humar, Marc Azemar, Martina Maurer, and Bernd Groner |
| DQB1*06:02-Associated Pathogenic Anti-Myelin Autoimmunity in Multiple Sclerosis-Like Disease: Potential Function of DQB1*06:02 as a Disease-Predisposing Allele |
| Nathali Kaushansky and Avraham Ben-Nun |
|
